COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced the initiation of a Phase III pivotal trial evaluating Prochymal as a first line agent in the treatment of acute Graft vs. Host Disease (GVHD), a life threatening complication of bone marrow transplantation that currently has no approved treatment. This trial marks the third indication for which Prochymal has advanced into Phase III testing. The primary endpoint of this pivotal trial includes remission rates and increased patient survival. These endpoints are supported by data from the company’s Phase II trial for the same indication. Highlights from the 32 patient Phase II trial include:
